2022 Saudi Guideline for Chronic Kidney Disease: Blood Pressure Management and Kidney Replacement Therapy in Adults and Children
MeSH Terms
Renal Insufficiency (C12.050.351.968.419.780);
Renal Dialysis (E02.870.300, E02.912.800) ; Kidney Diseases (C12.050.351.968.419);
Renal Insufficiency, Chronic (C12.050.351.968.419.780.750);
Middle East (Z01.252.245.500); Saudi Arabia (Z01.252.245.500.750); Antihypertensive Agents (D27.505.954.411.162);
Angiotensin-Converting Enzyme Inhibitors (D27.505.519.389.745.085); Angiotensin Receptor Antagonists (D27.505.519.162); Adrenergic beta-Antagonists )D27.505.519.625.050.200.200); Adrenergic alpha-Antagonists (D27.505.519.625.050.200.100); Diuretics (D27.505.696.560.500); Calcium Channel Blockers (D27.505.519.562.249); Renal Replacement Therapy (E02.870); Attitude to Health (F01.100.150, N05.300.150); Hypertension, Renal (C12.050.351.968.419.331)
Guideline Contact
Dr Khalid Alhasan
Keywords
chronic kidney disease; clinical practice guideline; blood pressure measurement; antihypertensive agents; kidney replacement therapy
Date for Review
29/04/2027
Expected Publication Date
29/04/2022
Date of Last Evidence Search
10/01/2021
Methods Applied
GRADE-ADOLOPMENT; AGREE II; Systematic review; Risk of Bias; GRADE
Publication Scope
assessment
counselling
management
Patient education
treatment
Countries of Application
Kingdom of Saudi Arabia
Guideline Publication Status
Development
Languages
English
Authors
Saudi CKD Group
Willingness to Collaborate
No